{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:04:21Z","timestamp":1773983061017,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.vaccine.2018.01.038","type":"journal-article","created":{"date-parts":[[2018,1,20]],"date-time":"2018-01-20T07:53:19Z","timestamp":1516434799000},"page":"1116-1125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway"],"prefix":"10.1016","volume":"36","author":[{"given":"Sabina","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Guzzetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmira","family":"Flem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazina","family":"Mirinaviciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"Scalia Tomba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piero","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9544","key":"10.1016\/j.vaccine.2018.01.038_b0005","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(06)69561-5","article-title":"Varicella","volume":"368","author":"Heininger","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.038_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/003591576505800106","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc Roy Soc Med"},{"issue":"9334","key":"10.1016\/j.vaccine.2018.01.038_b0015","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(02)09837-9","article-title":"Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study","volume":"360","author":"Thomas","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.038_b0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/vim.2010.0031","article-title":"Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents","volume":"24","author":"Ogunjimi","year":"2011","journal-title":"Viral Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.038_b0025","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jmv.23749","article-title":"Serology indicates cytomegalovirus infection is associated with varicella-zoster virus reactivation","volume":"86","author":"Ogunjimi","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2018.01.038_b0030","doi-asserted-by":"crossref","unstructured":"Ogunjimi B, Van den Bergh J, Meysman P, Heynderickx S, Bergs K, Jansen HN, et al. Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox. Sci Rep-UK 2017; 7.","DOI":"10.1038\/s41598-017-01024-8"},{"issue":"45","key":"10.1016\/j.vaccine.2018.01.038_b0035","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1016\/j.vaccine.2007.07.036","article-title":"The comparative seroepidemiology of varicella zoster virus in 11 countries in the European region","volume":"25","author":"Nardone","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.038_b0040","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1006\/bulm.1999.0126","article-title":"Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles","volume":"61","author":"Schuette","year":"1999","journal-title":"B Math Biol"},{"issue":"19","key":"10.1016\/j.vaccine.2018.01.038_b0045","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2018.01.038_b0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1017\/S0950268809990768","article-title":"Modelling the impact of varicella vaccination on varicella and zoster","volume":"138","author":"Karhunen","year":"2010","journal-title":"Epidemiol Infect"},{"issue":"19","key":"10.1016\/j.vaccine.2018.01.038_b0055","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1016\/j.vaccine.2010.02.079","article-title":"Modeling the impact of one-and two-dose varicella vaccination on the epidemiology of varicella and zoster","volume":"28","author":"Brisson","year":"2010","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2018.01.038_b0060","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","article-title":"Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England","volume":"29","author":"van Hoek","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2018.01.038_b0065","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/aje\/kwv240","article-title":"The epidemiology of herpes zoster after varicella immunization under different biological hypotheses: perspectives from mathematical modeling","volume":"183","author":"Guzzetta","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.vaccine.2018.01.038_b0070","doi-asserted-by":"crossref","first-page":"e60732","DOI":"10.1371\/journal.pone.0060732","article-title":"Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries","volume":"8","author":"Poletti","year":"2013","journal-title":"PloS one"},{"issue":"7","key":"10.1016\/j.vaccine.2018.01.038_b0075","first-page":"1766","article-title":"Current and future effects of varicella and herpes zoster vaccination in Germany\u2013insights from a mathematical model in a country with universal varicella vaccination","volume":"12","author":"Horn","year":"2016","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2018.01.038_b0080","doi-asserted-by":"crossref","unstructured":"van Lier A, Lugn\u00e9r A, Opstelten W, Jochemsen P, Wallinga J, Schellevis F, et al. Distribution of health effects and cost-effectiveness of varicella vaccination are shaped by the impact on herpes zoster. EBioMedicine 2015; 2(10):1494\u20139. 10.1016\/j.ebiom.2015.08.017. [eCollection 2015].","DOI":"10.1016\/j.ebiom.2015.08.017"},{"key":"10.1016\/j.vaccine.2018.01.038_b0085","unstructured":"ECDC GUIDANCE. Varicella vaccination in the European Union; 2015 <http:\/\/ecdc.europa.eu\/_layouts\/forms\/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90>."},{"key":"10.1016\/j.vaccine.2018.01.038_b0090","unstructured":"European Medicines Agency. EMEA: Zostavax. European public assessment report. Summary of product characteristics; 2009. <www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000674\/WC500053462.pdf>."},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.038_b0095","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.038_b0100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12879-016-1581-4","article-title":"Varicella-zoster virus susceptibility and primary healthcare consultations in Norway","volume":"16","author":"Rimseliene","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.038_b0105","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/INF.0000000000001656","article-title":"Varicella-related primary health-care visits, hospitalizations and mortality in norway, 2008\u20132014","volume":"36","author":"Mirinaviciute","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.01.038_b0110","unstructured":"Norwegian Institute of Public Health. Varicella- and herpes zoster vaccination - guidelines for healthcare professionals (Varicella- og herpes zostervaksinasjon - veileder for helsepersonell); 2016. <https:\/\/www.fhi.no\/nettpub\/vaksinasjonsveilederen\/vaksiner-mot-de-enkelte-sykdommene\/varicella--og-herpes-zostervaksinas\/>."},{"issue":"39","key":"10.1016\/j.vaccine.2018.01.038_b0115","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1016\/j.vaccine.2016.08.017","article-title":"Uptake and timeliness of rotavirus vaccination in Norway: the first year post-introduction","volume":"34","author":"Salamanca","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.038_b0120","doi-asserted-by":"crossref","first-page":"e0176845","DOI":"10.1371\/journal.pone.0176845","article-title":"The natural history of varicella zoster virus infection in Norway: further insights on exogenous boosting and progressive immunity to herpes zoster","volume":"12","author":"Marangi","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vaccine.2018.01.038_b0125","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/aje\/kws370","article-title":"Hope-Simpson's progressive immunity hypothesis as a possible explanation for herpes zoster incidence data","volume":"177","author":"Guzzetta","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"9925","key":"10.1016\/j.vaccine.2018.01.038_b0130","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(12)61461-5","article-title":"Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial","volume":"383","author":"Prymula","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.038_b0135","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jama.292.6.704","article-title":"Contagiousness of varicella in vaccinated cases: a household contact study","volume":"292","author":"Seward","year":"2004","journal-title":"J Am Med Assoc"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.038_b0140","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","article-title":"The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination","volume":"28","author":"Civen","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.038_b0145","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/infdis\/jit405","article-title":"Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005\u20132009","volume":"208","author":"Weinmann","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.038_b0150","doi-asserted-by":"crossref","unstructured":"Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, Jacobsen SJ. Declining effectiveness of herpes zoster vaccine in adults aged\u2265 60 years. J Infect Dis 2016; 213(12): 1872\u201375. [jiw047].","DOI":"10.1093\/infdis\/jiw047"},{"key":"10.1016\/j.vaccine.2018.01.038_b0155","unstructured":"Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR, Centers for Disease Control and Prevention (CDC). Update on recommendations for use of herpes zoster vaccine. MMWR-Morbid Mortal W 2014; 63(33): 729\u201331."},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.038_b0160","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1017\/S0950268811002640","article-title":"The health and economic burden of chickenpox and herpes zoster in Belgium","volume":"140","author":"Bilcke","year":"2012","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2018.01.038_b0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/1471-2334-10-230","article-title":"Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study","volume":"10","author":"Gialloreti","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.038_b0170","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","article-title":"The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.038_b0175","unstructured":"Bilcke J, van Hoek AJ, Beutels P. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? Human Vacc. Immunotherapeut. ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: <http:\/\/www.tandfonline.com\/loi\/khvi20>."},{"issue":"6 Suppl 2","key":"10.1016\/j.vaccine.2018.01.038_b0180","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"issue":"11","key":"10.1016\/j.vaccine.2018.01.038_b0185","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/0003-4819-159-11-201312030-00006","article-title":"Examination of links between herpes zoster incidence and childhood varicella vaccination","volume":"159","author":"Hales","year":"2013","journal-title":"Ann Intern Med"},{"issue":"282","key":"10.1016\/j.vaccine.2018.01.038_b0190","first-page":"2014","article-title":"The impact of demographic changes on the epidemiology of herpes zoster: Spain as a case study","volume":"2015","author":"Marziano","year":"1804","journal-title":"P Roy Soc B-Biol Sci, The Royal Soci"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.038_b0195","doi-asserted-by":"crossref","first-page":"e66485","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review","volume":"8","author":"Ogunjimi","year":"2013","journal-title":"PloS one"},{"issue":"5","key":"10.1016\/j.vaccine.2018.01.038_b0200","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/cid\/cir436","article-title":"Does monastic life predispose to the risk of Saint Anthony\u2019s fire (herpes zoster)?","volume":"53","author":"Gaillat","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2018.01.038_b0205","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2105\/AJPH.2009.160002","article-title":"Herpes zoster and exposure to the varicella zoster virus in an era of varicella vaccination","volume":"100","author":"Donahue","year":"2010","journal-title":"Am J Public Health"},{"issue":"27\u201330","key":"10.1016\/j.vaccine.2018.01.038_b0210","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/S0264-410X(03)00459-6","article-title":"Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage","volume":"21","author":"Goldman","year":"2003","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2018.01.038_b0215","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1086\/430325","article-title":"Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992\u20132002","volume":"191","author":"Jumaan","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2018.01.038_b0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2458-5-68","article-title":"The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998\u20132003","volume":"5","author":"Yih","year":"2005","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2018.01.038_b0225","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1542\/peds.2008-0567","article-title":"Varicella prevention in the United States: a review of successes and challenges","volume":"122","author":"Marin","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.038_b0230","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/522162","article-title":"The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review","volume":"197","author":"Reynolds","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.038_b0235","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.vaccine.2012.05.050","article-title":"Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data","volume":"31","author":"Goldman","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.038_b0240","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/ciw296","article-title":"Increasing incidence of herpes zoster over a 60-year period from a population-based study","volume":"63","author":"Kawai","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.038_b0245","doi-asserted-by":"crossref","first-page":"e07116","DOI":"10.7554\/eLife.07116","article-title":"Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster","volume":"4","author":"Ogunjimi","year":"2015","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.vaccine.2018.01.038_b0250","doi-asserted-by":"crossref","first-page":"e0163636","DOI":"10.1371\/journal.pone.0163636","article-title":"Estimating age-specific immunity and force of infection of varicella zoster virus in Norway using mixture models","volume":"11","author":"Del Fava","year":"2016","journal-title":"PloS one"},{"issue":"2","key":"10.1016\/j.vaccine.2018.01.038_b0255","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1017\/S0950268816002296","article-title":"Optimal vaccine schedules to maintain measles elimination with a two-dose routine policy","volume":"145","author":"McKee","year":"2017","journal-title":"Epidemiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:23:42Z","timestamp":1759400622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18300732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0264410X18300732"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}